Probe • Vol LXII • No. 3 • May–Aug 2023 • i Editorial Dear Doctor, We are delighted to announce that 2023 marks a milestone year for some of Himalaya’s products—Bonnisan completes 50 years, and Evecare, Confido, and OphthaCare complete 25 years in their journey of bestowing wellness. Thank you for your continual support for Himalaya’s products, doctor! This issue of Probe brings to you yet another collection of interesting medical updates. The uncertainties associated with platelet levels during dengue fever can be life-threatening. Thrombocytopenia is thus considered a significant predictor of the clinical severity of dengue. Know more about the mechanisms involved in thrombocytopenia associated with dengue fever in the From Other Pages section. This section also features an article on how hormones, other than androgens, can trigger the development of female pattern hair loss. Excerpts from the preclinical and clinical trial reports that prove the efficacy of Liv.52 DS in the management of drug-induced liver injury and nonalcoholic steatohepatitis, Septilin in the management of respiratory tract infections, and Liv.52 in the management of infective hepatitis are featured in the Evidence-Based Insights section. An excerpt of a recently published clinical study that shows the effect of Liv.52 DS Tablets on various liver parameters in nonalcoholic fatty liver disease is featured in the Latest Research section. Besides, engaging articles about different vitamin deficiencies seen in children and the pharmacologic significance of the herbs Tinospora cordifolia, Terminalia arjuna, and Syzygium aromaticum are part of this issue. We hope you find this issue’s collection of articles informative. — Editor
RkJQdWJsaXNoZXIy MjAwNDg=